4.7 Review

Epigenetics in the Human Brain

Journal

NEUROPSYCHOPHARMACOLOGY
Volume 38, Issue 1, Pages 183-197

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/npp.2012.78

Keywords

DNA methylation; DNA hydroxymethylation; post-translational histone modification; chromosome conformation; postmortem brain; psychiatric disease

Funding

  1. National Institutes of Health
  2. DARPA
  3. Autism Speaks
  4. Rostock Group
  5. [R01MH093332]
  6. [R01MH081943]
  7. [R01086509]
  8. [R01 AG029360]
  9. NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH096890, R01MH093332, R01MH086509, R01MH081943] Funding Source: NIH RePORTER
  10. NATIONAL INSTITUTE ON AGING [R01AG029360] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Many cellular constituents in the human brain permanently exit from the cell cycle during pre- or early postnatal development, but little is known about epigenetic regulation of neuronal and glial epigenomes during maturation and aging, including changes in mood and psychosis spectrum disorders and other cognitive or emotional disease. Here, we summarize the current knowledge base as it pertains to genome organization in the human brain, including the regulation of DNA cytosine methylation and hydroxymethylation, and a subset of (altogether 4100) residue-specific histone modifications associated with gene expression, and silencing and various other functional chromatin states. We propose that high-resolution mapping of epigenetic markings in postmortem brain tissue or neural cultures derived from induced pluripotent cells (iPS), in conjunction with transcriptome profiling and whole-genome sequencing, will increasingly be used to define the molecular pathology of specific cases diagnosed with depression, schizophrenia, autism, or other major psychiatric disease. We predict that these highly integrative explorations of genome organization and function will provide an important alternative to conventional approaches in human brain studies, which mainly are aimed at uncovering group effects by diagnosis but generally face limitations because of cohort size. Neuropsychopharmacology Reviews (2013) 38, 183-197; doi: 10.1038/npp.2012.78; published online 30 May 2012

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available